Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

The GBA Multimodal Study in Parkinson's Disease

Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.

Who May Be Eligible (Plain English)

Who May Qualify: - heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism; - age 18 to 80 years. Who Should NOT Join This Trial: - co-occurrence of other neurological disorders; - implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices); - severe claustrophobia; - intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects); - ongoing treatment with cholinergic drugs Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism; * age 18 to 80 years. Exclusion Criteria: * co-occurrence of other neurological disorders; * implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices); * severe claustrophobia; * intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects); * ongoing treatment with cholinergic drugs

Treatments Being Tested

DIAGNOSTIC_TEST

PET scan

3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.

DIAGNOSTIC_TEST

neuroQWERTY

Analysis of free-text typing in a computer and/or a touch-screen device.

Locations (3)

Oregon Health & Science University
Portland, Oregon, United States
University of Washington
Seattle, Washington, United States
Pacific Parkinson's Research Centre | University of British Columbia
Vancouver, British Columbia, Canada